These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10762127)

  • 21. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacology of levodopa-induced dyskinesia.
    Nutt JG
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
    Nutt JG
    Mov Disord; 2007 Jan; 22(1):1-9. PubMed ID: 16958130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of levodopa-induced dyskinesias.
    Calon F; Grondin R; Morissette M; Goulet M; Blanchet PJ; Di Paolo T; Bédard PJ
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S70-8. PubMed ID: 10762134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Olanow CW; Gracies JM; Goetz CG; Stoessl AJ; Freeman T; Kordower JH; Godbold J; Obeso JA
    Mov Disord; 2009 Feb; 24(3):336-43. PubMed ID: 19006186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Variance in effects of subthalamic nucleus stimulation].
    Okiyama R; Yokochi F; Taniguchi M; Takahashi H; Hasegawa N; Hamada I
    No To Shinkei; 2002 Oct; 54(10):883-8. PubMed ID: 12476577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):759-77. PubMed ID: 27091215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Problems with long-term levodopa therapy for Parkinson's disease.
    Marsden CD
    Clin Neuropharmacol; 1994; 17 Suppl 2():S32-44. PubMed ID: 9358193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
    Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL
    Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.